




9 FEBRUARY 2021

LGP SECURES FIRM COMMITMENTS TO RAISE \$22 MILLION

ASX ANNOUNCEMENT

Highlights:

-  Little Green Pharma has received firm commitments to raise \$22 million by way of a Placement to new and existing institutional and high net worth investors
-  Proceeds of the Placement will enable LGP to execute the Company's next phase of growth
-  A non-underwritten Share Purchase Plan to raise up to \$5 million will be offered to eligible shareholders on the same terms as the Placement

Little Green Pharma Ltd (ASX: LGP, "LGP" or the "Company") is pleased to announce that it has received firm commitments to raise approximately \$22 million (before costs) by way of a placement of shares ("Placement") to new and existing sophisticated, experienced, and professional investors.

LGP will also offer a Share Purchase Plan ("SPP") to eligible shareholders to raise up to \$5 million.

The Company will issue 34 million new fully paid ordinary shares ("New Shares") under the Placement at an issue price of \$0.65 per New Share ("Issue Price"). The Placement received strong support from high net worth investors and will see several institutional investors enter the Company's shareholder register.

Proceeds of the Placement will enable LGP to execute the Company's next phase of growth by accelerating sales and marketing efforts in Australia and offshore markets; expanding cultivation and manufacturing capacity; and providing general working capital.



Commenting on the Placement, Little Green Pharma Managing Director Fleta Solomon said:

“We’re highly encouraged by the strong support shown by new and existing shareholders for Little Green Pharma. I’d like to thank our existing shareholders for their continued support and would like to welcome new investors to the Little Green Pharma family.

“Little Green Pharma has gone from strength to strength, and has achieved immense growth in the last year, most recently setting new records for quarterly revenue, unit sales, and patient numbers. The Company continues to successfully execute upon our growth strategy, with a number of significant milestones achieved, including:

- *first commercial exports to the UK;*
- *first commercial export of oil and flower medicines to Germany;*
- *winning a French government tender for a national trial of cannabis medicines; and*
- *new product launches.*

“We expect the next 12 months to be very exciting for the Company and look forward to reporting on our continued success.”

Canaccord Genuity (Australia) Limited acted as Lead Manager to the Placement and has been appointed as Corporate Advisor to the Company.

Placement details

The Issue Price of \$0.65 per New Share represents a 8.4% discount to the 20-day Volume Weighted Average Price (“VWAP”) up to and including 4 February 2021 and a 30.5% discount to the last traded price (as at 4 February 2021).

The New Shares will be issued under the Company’s available ASX listing rule 7.1 (19,853,257 shares) and 7.1A (14,146,743 shares) placement capacity and will rank pari passu with existing shares in the Company. Settlement of the Placement is expected to occur on or about Monday, 15 February 2021.

Share Purchase Plan (SPP) details

LGP intends to offer the opportunity to all eligible shareholders of the Company as at 7:00pm AEDT (Australian Eastern Daylight Time) on Monday, 8 February 2021 (“**Record Date**”) with a registered address in Australia or New Zealand (“**Eligible Shareholders**”) to subscribe for up to \$30,000 of fully paid ordinary shares in a non-underwritten Share Purchase Plan (“**SPP Shares**”), to raise up to \$5 million.

Shares under the SPP will be offered at a fixed price of \$0.65 per share, being the same price as the Issue Price under the Placement.

The Company reserves the right to scale back applications under the SPP at its absolute discretion. The Company may decide to accept applications (in whole or in part) in its absolute discretion. SPP Shares will rank equally with the Company’s existing ordinary shares on issue. No brokerage or commissions are payable in respect of subscribing for shares under the SPP.



The offer under the SPP will be made on the basis of the information contained in the Share Purchase Plan offer booklet (“**SPP Offer Booklet**”), which will be dispatched to Eligible Shareholders on or about Monday, 15 February 2021 and made available following its lodgement with ASX.

Any Eligible Shareholder who wishes to participate in the SPP should consider the SPP Offer Booklet before deciding whether to apply for Shares under that plan and any such application must be made in accordance with, and pursuant to the terms and conditions set out in the SPP Offer Booklet. The SPP is proposed to open on Monday, 15 February 2021, and is scheduled to close at 5pm AEDT on Wednesday, 3 March 2021. Participation in the SPP will be open to all Eligible Shareholders.

Timetable of key dates

Below is an indicative timetable for the SPP:

Event	Time / Date
SPP Record Date	7:00pm AEDT Monday, 8 February 2021
SPP offer period opens	Monday, 15 February 2021
SPP Offer Booklet dispatched	Monday, 15 February 2021
SPP offer period closes	Wednesday, 3 March 2021
Announcement of result of SPP	Monday, 8 March 2021
SPP allotment date	Thursday, 11 March 2021
Expected Date of ASX Quotation of SPP Shares	Friday, 12 March 2021

Note: All dates and times are indicative and LGP reserves the right to amend any or all of these events, dates and times subject to the Corporations Act 2001 (Cth), ASX Listing Rules and other applicable laws. All times and dates are in reference to Sydney, Australia time.

For more information on the SPP, Eligible Shareholders may contact the Company’s share registry, Computershare, on the following numbers:

- within Australia: 1300 850 505
- within New Zealand: +61 3 9415 4000

ENDS

BY ORDER OF THE BOARD



Alistair Warren
Company Secretary

For further information please contact:

Alistair Warren
Company Secretary
Little Green Pharma
E: alistair@lgpharma.com.au
M: +61 8 6280 0050

Fleta Solomon
Managing Director
Little Green Pharma
E: fleta@lgpharma.com.au
M: +41 782 260 200



About Little Green Pharma

Little Green Pharma is a vertically integrated medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has an indoor cultivation facility and manufacturing facility in Western Australia for the production of its own-branded range of GMP-grade medicinal cannabis products.

Little Green Pharma products comply with all required Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: www.computershare.com.au/easyupdate/lgp

